NTHI Projected Dividend Yield
NeOnc Technologies Holdings Inc ( NASDAQ : NTHI )NeOnc Technologies Holdings is a clinical-stage life sciences company engaged on the development and commercialization of central nervous system therapeutics designed to address the persistent challenges of overcoming the blood-brain barrier. Co. is engaged in the research and development of therapies for the treatment of central nervous system disorders. NeOnc has two lead products: NEO100 and NEO212. NEO100 is a purified form of perillyl acid, administered to brain cancer patients via intranasal delivery. Additionally, NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. 21 YEAR PERFORMANCE RESULTS |
NTHI Dividend History Detail NTHI Dividend News NTHI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |